All News

Conv3.jpg

EULAR 2022 Featured Industry Abstracts

Jack Cush, MD

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Read Article
RheumNow Podcast square

Recommendations – Good & Bad (5.27.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Read Article
child.guttate.psoriasis

Psoriasis and Nonalcoholic Fatty Liver Disease

Jack Cush, MD

A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).

Read Article
psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

Jack Cush, MD

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

Jack Cush, MD

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
FDA.Safety.jpg

Bimekizumab Development Delayed by FDA

Jack Cush, MD

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

Jack Cush, MD

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.

Read Article
psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

Jack Cush, MD

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

Jack Cush, MD

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A

Read Article
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011, Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation... https://t.co/u86Vd8bFGr #MedEdTwitter https://t.co/IpKqPoWM9R

Links:

Dr. John Cush RheumNow ( View Tweet)
🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid #arthritis, axSPA, PsA etc... A useful checklist ✅ to keep in the pocket prepared with @DocFelten #Rheumatology #EULAR2022 https://t.co/cfc4VaF6GZ
Laurent ARNAUD Lupusreference ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
May 2022 EMA meeting the CHMP recommended new indications for Cosentyx (juvenile PsA, Enthesitis-related arthritis), Olumiant (alopecia areata), Rinvoq (ulcerative colitis) and Xeljanz (ankylosing spondylitis). EMA approval pending https://t.co/KauDY6e8zS https://t.co/mmv4G9jHI7

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic Persistence in Psoriatic Arthritis and Psoriasis Recent studies examined the durability and persistence of biologic agents in patients with PSO and PsA and while some differences were noted overall persistence was low 3 years later. https://t.co/sqxVaLnXEY https://t.co/yUPWYkRxva

Links:

Dr. John Cush RheumNow ( View Tweet)
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Pregnancy Paradox: How Stopping Drugs Leads to Greater Harm Uma Mahadevan, MD talks about the pregnancy paradox and how stopping medications in pregnancy to protect the fetus can actually lead to greater harm. https://t.co/HYO5BdjwzZ https://t.co/IGeZ3O8Dno

Links:

Dr. John Cush RheumNow ( View Tweet)
⭐️Ethics of placebo-controlled trials in PsA ➡️move toward active comparator designs. Need to use measures of deeper response (e.g., ACR 50, PASI100). ⭐️Assesing safety: LTE studies not adequate. Use of phase 4 studies or observational data but beware confounding by indication

Rheum Cat rheum_cat ( View Tweet)

We had a great TNR this week. Playback now available in case you missed it. This webinar presented excerpts from these lectures along with Q & A Psoriatic Arthritis Guidelines Drug Targeting in PsA PsA Registries and Real World Data https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×